Metformin HCl Extended Release Tablets Recalled

News
Article

Nostrum Laboratories is recalling Metformin HCl Extended Release Tablets because of NDMA above the acceptable daily intake limit.

Nostrum Laboratories (Kansas City, MO) announced on Nov. 2, 2020 that it was voluntarily recalling two lots of Metformin HCl Extended Release Tablets, USP 750 mg because of levels of nitrosamine (NDMA) impurities above the acceptable daily intake (ADI) limit. NDMA is classified as a probable human carcinogen.

The recalled lots (NDC 29033-056-01; lots MET200101 and MET200301) have an expiry date of 05/2022 and were distributed nationwide to wholesalers. The company is directing pharmacies to return the recalled product to the place of purchase.

Metformin HCl Extended Release Tablets, USP 750 mg are used to improve blood glucose control in adults with type 2 diabetes mellitus, according to the company. “Consumers should consult a healthcare professional to obtain a replacement or a different treatment option. It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their healthcare professional,” the company stated in a press release.

Adverse events associated with the recall may be reported to FDA through the agency’s MedWatch program.

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes